JP2024522988A - ペプチドおよび使用方法 - Google Patents

ペプチドおよび使用方法 Download PDF

Info

Publication number
JP2024522988A
JP2024522988A JP2023574133A JP2023574133A JP2024522988A JP 2024522988 A JP2024522988 A JP 2024522988A JP 2023574133 A JP2023574133 A JP 2023574133A JP 2023574133 A JP2023574133 A JP 2023574133A JP 2024522988 A JP2024522988 A JP 2024522988A
Authority
JP
Japan
Prior art keywords
seq
dose
administered
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522988A5 (https=
Inventor
ニール ケイ． クリシュナ
ケンジ クニオン
ウルリヒ ティーネル
Original Assignee
レアルタ ライフ サイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レアルタ ライフ サイエンシズ インコーポレイテッド filed Critical レアルタ ライフ サイエンシズ インコーポレイテッド
Publication of JP2024522988A publication Critical patent/JP2024522988A/ja
Publication of JP2024522988A5 publication Critical patent/JP2024522988A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/12011—Astroviridae
    • C12N2770/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023574133A 2021-06-01 2022-05-31 ペプチドおよび使用方法 Pending JP2024522988A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163195401P 2021-06-01 2021-06-01
US63/195,401 2021-06-01
US202163279423P 2021-11-15 2021-11-15
US63/279,423 2021-11-15
PCT/US2022/031559 WO2022256304A1 (en) 2021-06-01 2022-05-31 Peptides and methods of use

Publications (2)

Publication Number Publication Date
JP2024522988A true JP2024522988A (ja) 2024-06-25
JP2024522988A5 JP2024522988A5 (https=) 2025-06-09

Family

ID=84323526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574133A Pending JP2024522988A (ja) 2021-06-01 2022-05-31 ペプチドおよび使用方法

Country Status (10)

Country Link
US (1) US20240209036A1 (https=)
EP (1) EP4346866A4 (https=)
JP (1) JP2024522988A (https=)
KR (1) KR20240016323A (https=)
AU (1) AU2022286333A1 (https=)
BR (1) BR112023024988A2 (https=)
CA (1) CA3215620A1 (https=)
IL (1) IL308683A (https=)
MX (1) MX2023014326A (https=)
WO (1) WO2022256304A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094372A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10005818B2 (en) * 2010-07-21 2018-06-26 Realta Holdings, Llc Derivative peptide compounds and methods of use
JP6698276B2 (ja) * 2012-01-16 2020-05-27 アトックス バイオ リミテッド 細菌感染の治療用の合成ペプチド
LT3286181T (lt) * 2015-04-22 2021-04-26 Rigel Pharmaceuticals, Inc. Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
EP3740074B1 (en) * 2018-01-09 2024-11-06 ReAlta Holdings, LLC Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Also Published As

Publication number Publication date
EP4346866A4 (en) 2025-03-19
CA3215620A1 (en) 2022-12-08
AU2022286333A1 (en) 2023-11-02
KR20240016323A (ko) 2024-02-06
AU2022286333A9 (en) 2023-11-16
IL308683A (en) 2024-01-01
BR112023024988A2 (pt) 2024-02-20
MX2023014326A (es) 2023-12-13
EP4346866A1 (en) 2024-04-10
WO2022256304A1 (en) 2022-12-08
US20240209036A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
US10208089B2 (en) Modulation of complement activity
US12239684B2 (en) Modulators of complement activity
JP6251827B2 (ja) 炎症性腸疾患の経口治療
AU2021202648A1 (en) Modulation of cellular stress
WO2012174055A1 (en) Wound healing using complement inhibitors
JP2024522988A (ja) ペプチドおよび使用方法
EP2548883A2 (en) Peptide compounds that can be used as antibacterial agents
JP2026065064A (ja) ペプチドおよび使用方法
AU2018247928A1 (en) C4BP-based compounds for treating immunological diseases
US7745390B2 (en) Antimicrobial peptides
US20230414506A1 (en) Peptide formulations and methods of use
CN117396215A (zh) 肽和使用方法
JP7804672B2 (ja) ペプチドおよび使用方法
US20230192772A1 (en) Antimicrobial peptides and uses thereof
WO2020231989A1 (en) Compositions and methods for treatment of chronic granulomatous disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250530